440 related articles for article (PubMed ID: 16273367)
1. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
2. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
3. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
4. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
7. Amplification and co-regulators of androgen receptor gene in prostate cancer.
Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
Taplin ME; Balk SP
J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
[TBL] [Abstract][Full Text] [Related]
9. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
[TBL] [Abstract][Full Text] [Related]
10. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
11. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
14. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
15. Alterations of androgen receptor in prostate cancer.
Linja MJ; Visakorpi T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
[TBL] [Abstract][Full Text] [Related]
16. [Expression of androgen receptor protein in hormone refractory prostate cancer].
Zhang Y; Chen W; Hu XK; Gui ZN
Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446
[TBL] [Abstract][Full Text] [Related]
17. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
18. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
Wang G; Sadar MD
J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
[TBL] [Abstract][Full Text] [Related]
19. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test.
Ross JS
Adv Anat Pathol; 2007 Sep; 14(5):353-7. PubMed ID: 17717436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]